ZNF561 antisense RNA 1 contributes to angiogenesis in hepatocellular carcinoma through upregulation of platelet-derived growth Factor-D.

IF 1.4 4区医学 Q4 PHYSIOLOGY

Chinese Journal of Physiology Pub Date : 2022-09-01 DOI:10.4103/0304-4920.359795

Jihu Zheng, Zijian Guo, Zhanchao Wen, Huikang Chen

{"title":"ZNF561 antisense RNA 1 contributes to angiogenesis in hepatocellular carcinoma through upregulation of platelet-derived growth Factor-D.","authors":"Jihu Zheng, Zijian Guo, Zhanchao Wen, Huikang Chen","doi":"10.4103/0304-4920.359795","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma is a common malignant tumor with high recurrence rate. Long non-coding RNA (lncRNA) ZNF561 antisense RNA 1 (ZNF561-AS1) functions as an oncogenic lncRNA to promote the tumorigenesis of colorectal cancer. The role of ZNF561-AS1 in hepatocellular carcinoma remains unknown. ZNF561-AS1 was elevated in hepatocellular carcinoma tissues and cells. Silence of ZNF561-AS1 reduced cell viability and inhibited the proliferation of hepatocellular carcinoma. The angiogenesis of hepatocellular carcinoma was also suppressed by loss of ZNF561-AS1 with a decrease of angiopoietin 2, fibroblast growth factor 1, and vascular endothelial growth factor. ZNF561-AS1 bind to miR-302a-3p, and decreased expression of miR-302a-3p in hepatocellular carcinoma. Moreover, miR-302a-3p reduced platelet-derived growth factor-D (PDGFD) in hepatocellular carcinoma, and inhibition of miR-302a-3p attenuated ZNF561-AS1 silence-induced decrease of PDGFD. In conclusion, silence of ZNF561-AS1 might inhibit cell proliferation and angiogenesis of hepatocellular carcinoma through downregulation of miR-302a-3p-mediated PDGFD.</p>","PeriodicalId":10251,"journal":{"name":"Chinese Journal of Physiology","volume":"65 5","pages":"258-265"},"PeriodicalIF":1.4000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Physiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/0304-4920.359795","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHYSIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatocellular carcinoma is a common malignant tumor with high recurrence rate. Long non-coding RNA (lncRNA) ZNF561 antisense RNA 1 (ZNF561-AS1) functions as an oncogenic lncRNA to promote the tumorigenesis of colorectal cancer. The role of ZNF561-AS1 in hepatocellular carcinoma remains unknown. ZNF561-AS1 was elevated in hepatocellular carcinoma tissues and cells. Silence of ZNF561-AS1 reduced cell viability and inhibited the proliferation of hepatocellular carcinoma. The angiogenesis of hepatocellular carcinoma was also suppressed by loss of ZNF561-AS1 with a decrease of angiopoietin 2, fibroblast growth factor 1, and vascular endothelial growth factor. ZNF561-AS1 bind to miR-302a-3p, and decreased expression of miR-302a-3p in hepatocellular carcinoma. Moreover, miR-302a-3p reduced platelet-derived growth factor-D (PDGFD) in hepatocellular carcinoma, and inhibition of miR-302a-3p attenuated ZNF561-AS1 silence-induced decrease of PDGFD. In conclusion, silence of ZNF561-AS1 might inhibit cell proliferation and angiogenesis of hepatocellular carcinoma through downregulation of miR-302a-3p-mediated PDGFD.

查看原文本刊更多论文

ZNF561反义RNA 1通过上调血小板源性生长因子d参与肝细胞癌血管生成。

肝细胞癌是一种常见的恶性肿瘤，复发率高。长链非编码RNA (lncRNA) ZNF561反义RNA 1 (ZNF561- as1)作为一种致癌lncRNA促进结直肠癌的肿瘤发生。ZNF561-AS1在肝细胞癌中的作用尚不清楚。ZNF561-AS1在肝细胞癌组织和细胞中表达升高。沉默ZNF561-AS1可降低肝癌细胞活力，抑制肝癌细胞增殖。肝细胞癌的血管生成也被ZNF561-AS1的缺失所抑制，同时血管生成素2、成纤维细胞生长因子1和血管内皮生长因子的降低。ZNF561-AS1结合miR-302a-3p，降低miR-302a-3p在肝细胞癌中的表达。此外，miR-302a-3p可降低肝细胞癌中的血小板衍生生长因子d (PDGFD)，抑制miR-302a-3p可减弱ZNF561-AS1沉默诱导的PDGFD的降低。综上所述，ZNF561-AS1的沉默可能通过下调mir -302a-3p介导的PDGFD来抑制肝癌细胞增殖和血管生成。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Journal of Physiology 医学-生理学

CiteScore

2.30

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Chinese Journal of Physiology is a multidisciplinary open access journal. Chinese Journal of Physiology (CJP) publishes high quality original research papers in physiology and pathophysiology by authors all over the world. CJP welcomes submitted research papers in all aspects of physiology science in the molecular, cellular, tissue and systemic levels. Multidisciplinary sciences with a focus to understand the role of physiology in health and disease are also encouraged. Chinese Journal of Physiology accepts fourfold article types: Original Article, Review Article (Mini-Review included), Short Communication, and Editorial. There is no cost for readers to access the full-text contents of publications.